Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Patent court also sided with generic makers of Baraclude
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Apr 14, 2014 15:17:04
The patent court sided with the generic drug makers of Balaclude on April 11.

Jeil, Hanmi, and Dong-A ST were developing their generic versions of Balaclude after the court said last year that the companies didn’t infringe the patent right of Bristol-Myers Squibb (BMS).

BMS didn’t agree with the ruling and brought the case to the patent court. But the patent court supported the lower court’s ruling.

A pharmaceutical marketer said, “When all the patent issues are cleared, we can reduce exhausting disputes about the patent on the composition of the drug after the patent on the substance expires.”

BMS’s patent on the substance of Balraclude is doomed to expire in October 2014. Hanmi and Daewoong are currently challenging the substance patent on Baraclude.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com